In 1993, results showed that bevacizumab, a humanized monoclonal antibody, and called Avastin, binds specifically to all isoforms of VEGF-A and disrupts its activity and interactions with VEGFR-1 and -2, leading to a decrease in tumor growth. This evidence concerns the gene FLT1 and neoplasm.